Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy

Christian Jakob, MD, Peter Liebisch, MD, Ulrike Heider, MD, Martin Kaiser, MD, Jan Sterz, MD, Jessica Rademacher, MD, Claudia Fleissner, MD, Christian Müller, MD, Orhan Sezer, MD

Blood (2008) 112 (11): 2721.

https://doi.org/10.1182/blood.V112.11.2721.2721

Published: 2008

Journal Articles

Serum Concentrations of DKK-1 Correlate with the Extent of Bone Disease in Multiple Myeloma.

Martin Kaiser, MD, Maren Mieth, PhD, Peter Liebisch, MD, PhD, Susanne Rötzer, Christian Jakob, MD, Claudia Fleissner, MD, Edgar Braendle, MD, PhD, David Stover, PhD, Malte Peters, MD, PhD, Orhan Sezer, MD, PhD, Ulrike Heider, MD

Blood (2007) 110 (11): 3518.

https://doi.org/10.1182/blood.V110.11.3518.3518

Published: 2007

Journal Articles

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

Christian Jakob, MD, Peter Liebisch, MD, Karl Egerer, MD, Jan Sterz, MD, Martin Kaiser, MD, Susanne Rötzer, MD, Ulrike Heider, MD, Jessica Rademacher, MD, Claudia Fleissner, MD, Peter M. Kloetzel, PhD, Evangelos Terpos, MD, Orhan Sezer, MD

Blood (2007) 110 (11): 1475.

https://doi.org/10.1182/blood.V110.11.1475.1475

Published: 2007

Journal Articles

Bortezomib Inhibits Human Osteoclastogenesis.

Ivana Zavrski, MD, Monica Hecht, PhD, Holger Krebbel, Claudia Fleissner, MD, Maren Mieth, PhD, Martin Kaiser, MD, Ulrike Heider, MD, Christian Jakob, MD, Jan Sterz, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2006) 108 (11): 1395.

https://doi.org/10.1182/blood.V108.11.1395.1395

Published: 2006

Journal Articles

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma.

Ulrike Heider, MD, Martin Kaiser, MD, Ivana Zavrski, MD, Jan Sterz, MD, Christian Jakob, MD, Claudia Fleissner, MD, Monica Hecht, MD, Lorenz Kleeberg, MD, Christian Braun, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2006) 108 (11): 2509.

https://doi.org/10.1182/blood.V108.11.2509.2509

Published: 2006

Journal Articles

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma.

Jan Sterz, MD, Christian Jakob, MD, Ulrike Kuckelkorn, PhD, Hannes A. Braun, PhD, Martin Kaiser, MD, Claudia Fleissner, MD, Lorenz Kleeberg, MD, Ulrike Heider, MD, Kurt Possinger, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD, Ivana Zavrski, MD

Blood (2006) 108 (11): 3475.

https://doi.org/10.1182/blood.V108.11.3475.3475

Published: 2006

Journal Articles

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Christian Jakob, Karl Egerer, Peter Liebisch, Seval Türkmen, Ivana Zavrski, Ulrike Kuckelkorn, Ulrike Heider, Martin Kaiser, Claudia Fleissner, Jan Sterz, Lorenz Kleeberg, Eugen Feist, Gerd-R. Burmester, Peter-M. Kloetzel, Orhan Sezer

Blood (2006) 109 (5): 2100–2105.

https://doi.org/10.1182/blood-2006-04-016360

Published: 2006

Journal Articles

Bortezomib (PS-341) Sensitizes Multiple Myeloma Cell Lines to Etoposide-Induced Apoptosis.

Ivana Zavrski, MD, Martin Kaiser, MD, Marleen Rosche, MD, Ulrike Heider, MD, Christian Jakob, MD, Claudia Fleissner, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2005) 106 (11): 5166.

https://doi.org/10.1182/blood.V106.11.5166.5166

Published: 2005

Journal Articles

Histone Deacetylase Inhibitors Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma and Reduce VEGF Production.

Ulrike Heider, MD, Martin Kaiser, MD, Ivana Zavrski, MD, Jan Sterz, MD, Christian Jakob, MD, Claudia Fleissner, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2005) 106 (11): 4817.

https://doi.org/10.1182/blood.V106.11.4817.4817

Published: 2005

NARROW

Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy

Serum Concentrations of DKK-1 Correlate with the Extent of Bone Disease in Multiple Myeloma.

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

Bortezomib Inhibits Human Osteoclastogenesis.

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma.

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma.

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Bortezomib (PS-341) Sensitizes Multiple Myeloma Cell Lines to Etoposide-Induced Apoptosis.

Histone Deacetylase Inhibitors Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma and Reduce VEGF Production.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only